ENTITY
Sihuan Pharmaceutical Hldgs

Sihuan Pharmaceutical Hldgs (460 HK)

51
Analysis
Health CareChina
Sihuan Pharmaceutical Holdings Group Ltd. researches and develops cardiocerebral vascular drugs in China. The Company drugs address needs in the areas of anti-infective, metabolism, cardiovascular system, oncology and nervous system.
more
15 Nov 2024 08:27

Sihuan Pharmaceutical (460 HK): Buybacks, Now A Spin-Off

There appears considerable value to be unlocked via the spin-off of Xuanzhu Biopharm. Plus you have buyback support. I think this is worth a punt...

Logo
254 Views
Share
06 Oct 2024 09:23

China Healthcare Weekly (Oct.6) - WuXi to Sell Assets, Be Rational on China CXO, Sihuan Underperform

​Investors need to be rational on China CXO.Selling US/EU operations stabilizes WuXi's business, but geopolitical risk may persist. Sihuan's share...

Logo
402 Views
Share
18 Oct 2024 23:12

China Traditional Chinese Medicine (570 HK): Disaster as Offer Lapses, Potential Deal Break Price

This deal break caught many, including me, off guard. There are lessons to be learnt and questions to be asked. Shareholders will have a bruising...

Logo
1.2k Views
Share
bearishPegBio
05 Feb 2025 10:19

PegBio 派格生物 IPO: A (Supposedly) Straightforward GLP-1 Challenger Story

​PegBio plans to raise $100m in Hong Kong IPO, with focus on core product PB-117 as a GLP-1 challenger, but concerns arise upon closer examination...

Logo
258 Views
Share
17 Nov 2024 07:00

Last Week in Event SPACE: Seven & I, PA Gooddoctor, Nec Networks, Genscript/Legend, ASM PT, Hanwha

It’s Sunday! Pour yourself a coffee, grab a comfortable seat, and sift through a brief summary of insights on various events discussed during the...

Logo
537 Views
Share
x